kabutan

Oncolys BioPharma Inc.(4588) Summary

4588
TSE Growth
Oncolys BioPharma Inc.
1,685
JPY
+120
(+7.67%)
Jan 29, 1:38 pm JST
11.03
USD
Jan 28, 11:39 pm EST
Result
PTS
outside of trading hours
1,685
Jan 29, 1:38 pm JST
Summary Chart Historical News Financial Result
PER
PBR
28.5
Yield
ー%
Margin Trading Ratio
1,106.35
Stock Price
Jan 29, 2026
Opening Jan 29, 9:12 am
1,765 JPY 11.52 USD
Previous Close Jan 28
1,565 JPY 10.25 USD
High Jan 29, 9:23 am
1,777 JPY 11.61 USD
Low Jan 29, 9:32 am
1,657 JPY 10.83 USD
Volume
1,441,300
Trading Value
2.46B JPY 0.02B USD
VWAP
1704.05 JPY 11.13 USD
Minimum Trading Value
168,500 JPY 1,103 USD
Market Cap
0.05T JPY 0.32B USD
Number of Trades
5,130
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
2,918
1-Year High Dec 30, 2025
44,420
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 2,200 5,783,700 2628.95
Jan 16, 2026 100 5,972,900 59729.00
Jan 9, 2026 4,400 6,339,900 1440.89
Dec 26, 2025 6,300 6,739,100 1069.70
Dec 19, 2025 1,000 7,009,800 7009.80
Company Profile
Oncolys BioPharma Inc. is a drug discovery venture focusing on rare cancers and severe infectious diseases, utilizing proprietary virus technology.
Sector
Pharmaceuticals
Oncolys BioPharma Inc. promotes the development of cancer virus therapy and severe infectious disease treatments using its proprietary virus genetic modification technology. Its main pipeline includes Telomelysin, which specifically proliferates in cancer cells, and OBP-702, a next-generation Telomelysin with even more potent anti-cancer activity. Additionally, OBP-601, which has been developed as an HIV infection treatment, is now being repurposed as a treatment for neurodegenerative diseases. The company is also developing OBP-2011 as a viral infection treatment. Oncolys BioPharma Inc. is also working on TelomeScan, a cancer diagnostic agent for ultra-early detection or prognosis testing of cancer. The company employs a fabless management strategy to optimize development efficiency and expenses.